Moderna to Reveal Long-Term Efficacy Data for Respiratory Vaccines

Cambridge, Tuesday, 7 April 2026.
This April, Moderna will present late-breaking revaccination data for its flu and RSV vaccines, a critical step toward proving long-term efficacy in the competitive seasonal immunization market.